Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)

INTRODUCTION: Glycoprotein NMB is a transmembrane protein linked with poor prognosis and is expressed in most squamous lung cancer. Glembatumumab vedotin is an antibody-drug conjugate targeting glycoprotein NMB, administered intravenously every 3 weeks in this phase 1 study to determine the safety,...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Saad A., Sun, Zhuoxin, Dahlberg, Suzanne, Malhotra, Jyoti, Keresztes, Roger, Ikpeazu, Chukwuemeka, Ma, Patrick, Ramalingam, Suresh S., Pillai, Rathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474292/
https://www.ncbi.nlm.nih.gov/pubmed/34590018
http://dx.doi.org/10.1016/j.jtocrr.2021.100166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474292/
https://www.ncbi.nlm.nih.gov/pubmed/34590018
http://dx.doi.org/10.1016/j.jtocrr.2021.100166

Ejemplares similares